1
|
Vitti JN, Vitti R, Chu K, Mellis S. The ethics of clinical research in the era of COVID-19. Front Public Health 2024; 12:1359654. [PMID: 38510356 PMCID: PMC10950982 DOI: 10.3389/fpubh.2024.1359654] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2023] [Accepted: 02/20/2024] [Indexed: 03/22/2024] Open
Abstract
There is an urgent need for increased understanding of COVID-19 and strategies for its prevention, treatment, and mitigation. All participants in the research enterprise, including institutional review boards, have an ethical duty to protect participants and ensure that the benefits gained from such research do not conflict with the core principles that guided researchers prior to the pandemic. In this review, we discuss the ethical issues surrounding initiation and conduct of clinical trials, focusing on novel COVID-19 therapeutic, vaccine, or biospecimen research, using the principles of autonomy, beneficence, and justice. We discuss strategies to manage the practical challenges associated with the conduct of clinical trials, with an emphasis on maintaining the rights and welfare of research participants.
Collapse
Affiliation(s)
| | - Robert Vitti
- Regeneron Pharmaceuticals Inc., Tarrytown, NY, United States
| | - Karen Chu
- Regeneron Pharmaceuticals Inc., Tarrytown, NY, United States
| | - Scott Mellis
- Regeneron Pharmaceuticals Inc., Tarrytown, NY, United States
| |
Collapse
|
2
|
Higgs EF, Flood BA, Pyzer AR, Rouhani SJ, Trujillo JA, Gajewski TF. Insights from a Rapidly Implemented COVID-19 Biobank Using Electronic Consent and Informatics Tools. Biopreserv Biobank 2023; 21:166-175. [PMID: 35771982 PMCID: PMC10125396 DOI: 10.1089/bio.2021.0169] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Abstract
Biobanking during the COVID-19 pandemic presented unique challenges regarding patient enrollment, sample collection, and experimental analysis. This report details the ways in which we rapidly overcame those challenges to create a robust database of clinical information and patient samples while maintaining clinician and researcher safety. We developed a pipeline using REDCap (Research Electronic Data Capture) to coordinate electronic informed consent, sample collection, immunological assay execution, and data analysis for biobanking samples from patients with COVID-19. We then integrated immunological assay data with clinical data extracted from the electronic health record to link study parameters with clinical readouts. Of the 193 inpatients who participated in this study, 138 consented electronically and 56 provided paper consent. We collected and banked blood samples to measure circulating cytokines and chemokines, peripheral immune cell composition and activation status, anti-COVID-19 antibodies, and germline gene polymorphisms. In addition, we collected DNA and RNA from nasopharyngeal swabs to assess viral titer and microbiome composition by 16S sequencing. The rapid spread and contagious nature of COVID-19 required special considerations and innovative solutions to biobank samples quickly while protecting researchers and clinicians. Overall, this workflow and computational pipeline allowed for comprehensive immune profiling of 193 inpatients infected with COVID-19, as well as 89 outpatients, 157 patients receiving curbside COVID-19 testing, and 86 healthy controls. We describe a novel electronic framework for biobanking and analyzing patient samples during COVID-19, and present insights and strategies that can be applied more broadly to other biobank studies.
Collapse
Affiliation(s)
- Emily F. Higgs
- Department of Pathology, The University of Chicago, Chicago, Illinois, USA
| | - Blake A. Flood
- Department of Pathology, The University of Chicago, Chicago, Illinois, USA
| | - Athalia R. Pyzer
- Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois, USA
| | - Sherin J. Rouhani
- Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois, USA
| | - Jonathan A. Trujillo
- Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois, USA
| | - Thomas F. Gajewski
- Department of Pathology, The University of Chicago, Chicago, Illinois, USA
- Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois, USA
- The Ben May Department for Cancer Research, The University of Chicago, Chicago, Illinois, USA
| |
Collapse
|
3
|
Singh S, Cadigan RJ, Moodley K. Challenges to biobanking in LMICs during COVID-19: time to reconceptualise research ethics guidance for pandemics and public health emergencies? JOURNAL OF MEDICAL ETHICS 2022; 48:466-471. [PMID: 33980656 PMCID: PMC8117471 DOI: 10.1136/medethics-2020-106858] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/29/2020] [Revised: 03/20/2021] [Accepted: 04/20/2021] [Indexed: 06/12/2023]
Abstract
Biobanking can promote valuable health research that may lead to significant societal benefits. However, collecting, storing and sharing human samples and data for research purposes present numerous ethical challenges. These challenges are exacerbated when the biobanking efforts aim to facilitate research on public health emergencies and include the sharing of samples and data between low/middle-income countries (LMICs) and high-income countries (HICs). In this article, we explore ethical challenges for COVID-19 biobanking, offering examples from two past infectious disease outbreaks in LMICs where biobanking activities contributed to the perpetuation of global inequities. We focus on how the ethical imperative to promote the common good during public health emergencies can conflict with protecting the interests of biobank participants. We discuss how conducting biobank research under a waiver of informed consent during public health emergencies is ethically permissible, provided guidance is in place to prevent biopiracy and exploitation of vulnerable communities. We also highlight the need for biobank collaborations between LMICs and HICs to promote capacity building and benefit sharing. Finally, we offer guidance to promote the ethical oversight of biobanks and biobank research during the COVID-19 pandemic or other future public health emergencies.
Collapse
Affiliation(s)
- Shenuka Singh
- Faculty of Medicine and Health Sciences, Centre for Medical Ethics and Law, Stellenbosch University, Cape Town, South Africa
| | - Rosemary Jean Cadigan
- Social Medicine, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA
| | - Keymanthri Moodley
- Faculty of Medicine and Health Sciences, Centre for Medical Ethics and Law, University of Stellenbosch, Stellenbosch, Western Cape, South Africa
| |
Collapse
|
4
|
Ragan EJ, McCallum C, Marathe J, Cole M, Hofman M, Henderson AJ, Flack T, Miller NS, Burks EJ, Zhao GQ, Denis R, Lin NH, Jacobson KR, Andry CD, Pelton SI, Duffy ER, Bhadelia N. Pandemic Response Requires Research Samples: A U.S. Safety-Net Hospital's Experience and Call for National Action. Ann Intern Med 2021; 174:1727-1732. [PMID: 34724402 DOI: 10.7326/m21-2857] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Biorepositories provide a critical resource for gaining knowledge of emerging infectious diseases and offer a mechanism to rapidly respond to outbreaks; the emergence of the novel coronavirus, SARS-CoV-2, has proved their importance. During the COVID-19 pandemic, the absence of centralized, national biorepository efforts meant that the onus fell on individual institutions to establish sample repositories. As a safety-net hospital, Boston Medical Center (BMC) recognized the importance of creating a COVID-19 biorepository to both support critical science at BMC and ensure representation in research for its urban patient population, most of whom are from underserved communities. This article offers a realistic overview of the authors' experience in establishing this biorepository at the onset of the COVID-19 pandemic during the height of the first surge of cases in Boston, Massachusetts, with the hope that the challenges and solutions described are useful to other institutions. Going forward, funders, policymakers, and infectious disease and public health communities must support biorepository implementation as an essential element of future pandemic preparedness.
Collapse
Affiliation(s)
- Elizabeth J Ragan
- Section of Infectious Diseases and Research Operations, Boston Medical Center, Boston, Massachusetts (E.J.R.)
| | - Caitryn McCallum
- Section of Infectious Diseases, Boston Medical Center, and Center for Emerging Infectious Diseases Policy and Research, Boston University, Boston, Massachusetts (C.M.)
| | - Jai Marathe
- Section of Infectious Diseases, Boston Medical Center, Boston, Massachusetts (J.M., N.H.L., K.R.J.)
| | - Manisha Cole
- Department of Pathology and Laboratory Medicine, Boston Medical Center, Boston, Massachusetts (M.C., N.S.M., E.J.B., G.Q.Z.)
| | - Melissa Hofman
- Clinical Data Warehouse, Boston Medical Center, Boston, Massachusetts (M.H.)
| | - Andrew J Henderson
- Section of Infectious Diseases, Boston Medical Center, and Department of Microbiology, Boston University School of Medicine, Boston, Massachusetts (A.J.H.)
| | - Tyler Flack
- Research Operations, Boston Medical Center, Boston, Massachusetts (T.F.)
| | - Nancy S Miller
- Department of Pathology and Laboratory Medicine, Boston Medical Center, Boston, Massachusetts (M.C., N.S.M., E.J.B., G.Q.Z.)
| | - Eric J Burks
- Department of Pathology and Laboratory Medicine, Boston Medical Center, Boston, Massachusetts (M.C., N.S.M., E.J.B., G.Q.Z.)
| | - Grace Qing Zhao
- Department of Pathology and Laboratory Medicine, Boston Medical Center, Boston, Massachusetts (M.C., N.S.M., E.J.B., G.Q.Z.)
| | - Ridiane Denis
- General Clinical Research Unit, Boston University, Boston, Massachusetts (R.D.)
| | - Nina H Lin
- Section of Infectious Diseases, Boston Medical Center, Boston, Massachusetts (J.M., N.H.L., K.R.J.)
| | - Karen R Jacobson
- Section of Infectious Diseases, Boston Medical Center, Boston, Massachusetts (J.M., N.H.L., K.R.J.)
| | - Christopher D Andry
- Department of Pathology and Laboratory Medicine, Boston Medical Center, and Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, Massachusetts (C.D.A., E.R.D.)
| | - Stephen I Pelton
- Section of Pediatric Infectious Diseases, Department of Pediatrics, Boston University Medical Center, Department of Epidemiology, Boston University School of Public Health, and Maxwell Finland Laboratory for Infectious Diseases, Boston, Massachusetts (S.I.P.)
| | - Elizabeth R Duffy
- Department of Pathology and Laboratory Medicine, Boston Medical Center, and Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, Massachusetts (C.D.A., E.R.D.)
| | - Nahid Bhadelia
- Section of Infectious Diseases, Boston Medical Center, and Center for Emerging Infectious Diseases Policy and Research and National Emerging Infectious Diseases Laboratories, Boston University, Boston, Massachusetts (N.B.)
| |
Collapse
|
5
|
Osman I, Cotzia P, Moran U, Donnelly D, Arguelles-Grande C, Mendoza S, Moreira A. Correction to: The urgency of utilizing COVID-19 biospecimens for research in the heart of the global pandemic. J Transl Med 2021; 19:240. [PMID: 34082754 PMCID: PMC8173100 DOI: 10.1186/s12967-021-02883-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
An amendment to this paper has been published and can be accessed via the original article.
Collapse
Affiliation(s)
- Iman Osman
- The New York University Langone Health (NYULH) Center of Biospecimen Research and Development, Ofce of Science and Research, NYU Grossman School of Medicine, 522 First Avenue, SML405, New York, NY, 10016, USA.
| | - Paolo Cotzia
- The New York University Langone Health (NYULH) Center of Biospecimen Research and Development, Ofce of Science and Research, NYU Grossman School of Medicine, 522 First Avenue, SML405, New York, NY, 10016, USA
| | - Una Moran
- The New York University Langone Health (NYULH) Center of Biospecimen Research and Development, Ofce of Science and Research, NYU Grossman School of Medicine, 522 First Avenue, SML405, New York, NY, 10016, USA
| | - Douglas Donnelly
- The New York University Langone Health (NYULH) Center of Biospecimen Research and Development, Ofce of Science and Research, NYU Grossman School of Medicine, 522 First Avenue, SML405, New York, NY, 10016, USA
| | - Carolina Arguelles-Grande
- The New York University Langone Health (NYULH) Center of Biospecimen Research and Development, Ofce of Science and Research, NYU Grossman School of Medicine, 522 First Avenue, SML405, New York, NY, 10016, USA
| | - Sandra Mendoza
- The New York University Langone Health (NYULH) Center of Biospecimen Research and Development, Ofce of Science and Research, NYU Grossman School of Medicine, 522 First Avenue, SML405, New York, NY, 10016, USA
| | - Andre Moreira
- The New York University Langone Health (NYULH) Center of Biospecimen Research and Development, Ofce of Science and Research, NYU Grossman School of Medicine, 522 First Avenue, SML405, New York, NY, 10016, USA
| |
Collapse
|
6
|
Lapid MI, Meagher KM, Giunta HC, Clarke BL, Ouellette Y, Armbrust TL, Sharp RR, Wright RS. Ethical Challenges in COVID-19 Biospecimen Research: Perspectives From Institutional Review Board Members and Bioethicists. Mayo Clin Proc 2021; 96:165-173. [PMID: 33413815 PMCID: PMC7584427 DOI: 10.1016/j.mayocp.2020.10.021] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/01/2020] [Revised: 09/28/2020] [Accepted: 10/20/2020] [Indexed: 02/06/2023]
Abstract
Biospecimen research is a prominent investigative strategy that aims to provide novel insights into coronavirus disease 2019 (COVID-19), inform clinical trials, and develop effective, life-saving treatments. However, COVID-19 biospecimen research raises accompanying ethical concerns and practical challenges for investigators and participants. In this special article, we discuss the ethical issues that are associated with autonomy, beneficence, and justice in COVID-19 biospecimen research and describe strategies to manage the practical challenges, with an emphasis on protecting the rights and welfare of human research participants during a pandemic response. Appropriate institutional review board oversight and bioethics guidance for COVID-19 biospecimen research must maintain their focus on protecting the rights and welfare of research participants, despite the urgent need for more knowledge about the virus and the threat it poses to communities and nations.
Collapse
Affiliation(s)
- Maria I Lapid
- Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN.
| | - Karen M Meagher
- Division of Health Care Policy and Research, Mayo Clinic, Rochester, MN; Biomedical Ethics Research Program, Mayo Clinic, Rochester, MN
| | - Hannah C Giunta
- Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN
| | - Bart L Clarke
- Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, MN
| | - Yves Ouellette
- Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN
| | - Tamyra L Armbrust
- Office for Human Research Protection and Institutional Review Board, Mayo Clinic, Rochester, MN
| | - Richard R Sharp
- Division of Health Care Policy and Research, Mayo Clinic, Rochester, MN; Biomedical Ethics Research Program, Mayo Clinic, Rochester, MN; Center for Individualized Medicine, Mayo Clinic, Rochester, MN
| | - R Scott Wright
- Office for Human Research Protection and Institutional Review Board, Mayo Clinic, Rochester, MN; Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN
| |
Collapse
|
7
|
Allocca CM, Bledsoe MJ, Albert M, Anisimov SV, Bravo E, Castelhano MG, Cohen Y, De Wilde M, Furuta K, Kozlakidis Z, Martin D, Martins A, McCall S, Morrin H, Pugh RS, Schacter B, Simeon-Dubach D, Snapes E. Biobanking in the COVID-19 Era and Beyond: Part 1. How Early Experiences Can Translate into Actionable Wisdom. Biopreserv Biobank 2020; 18:533-546. [PMID: 33164554 DOI: 10.1089/bio.2020.0082] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
The era of COVID-19 has brought about a number of novel challenges for the global biobanking community. To better position the biobanking community to cope with current and future challenges, the International Society for Biological and Environmental Repositories (ISBER) COVID-19 Response Task Force was convened to identify needs and gaps in biobanking tools (existing resources that support good practice), for example, standards, best practices, business, etc. and to make recommendations to benefit the community. Toward these goals, the Task Force assembled a set of questions to explore individual biobanks' experiences, with emphasis on identification of key challenges and approaches, including tools employed. A survey was designed with the use of these questions and administered by ISBER. This article presents a summary of the aggregated data obtained from the survey responses, illustrating some of the major issues encountered and identifying which tools the survey respondents found most useful. In particular, this article focuses on the challenges identified during the early months of the COVID-19 era. Recommendations are provided to support biobank emergency preparedness for the future, address lessons learned, and propose solutions to bridge identified gaps. The analysis and the complete survey dataset will also inform the larger Task Force goal to develop specific tool recommendations.
Collapse
Affiliation(s)
- Clare M Allocca
- Standards Coordination Office, National Institute of Standards and Technology, Gaithersburg, Maryland, USA
| | - Marianna J Bledsoe
- Independent Consultant and Deputy Editor, Biopreservation and Biobanking, Colorado Springs, Colorado, USA
| | - Monique Albert
- Ontario Tumour Bank, Ontario Institute for Cancer Research, Toronto, Canada
| | | | - Elena Bravo
- Research Coordination and Support Service, Italian National Institute of Health, Rome, Italy
| | - Marta G Castelhano
- Cornell Veterinary Biobank, College of Veterinary Medicine, Cornell University, Ithaca, New York, USA
| | - Yehudit Cohen
- MIDGAM-Israel National Biobank for Research, Rehovot, Israel
| | | | - Koh Furuta
- Urayasu Warakuen Clinic, Urayasu, Japan
- Laboratory Service and Biobank Group, International Agency for Research on Cancer, World Health Organization, Lyon, France
| | - Zisis Kozlakidis
- Laboratory Service and Biobank Group, International Agency for Research on Cancer, World Health Organization, Lyon, France
| | - Dunja Martin
- Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures GmbH, Braunschweig, Germany
| | - Anabela Martins
- Micoteca da Universidade do Minho, Centro de Engenharia Biológica, Braga, Portugal
| | - Shannon McCall
- Department of Pathology, Duke University Health System, Durham, North Carolina, USA
| | - Helen Morrin
- Department of Pathology and Biomedical Science, University of Otago, Christchurch, New Zealand
| | - Rebecca S Pugh
- Chemical Sciences Division, National Institute of Standards and Technology, Charleston, South Carolina, USA
| | - Brent Schacter
- CancerCare Manitoba/University of Manitoba, Winnipeg, Canada
| | | | | |
Collapse
|
8
|
Maurano MT, Ramaswami S, Zappile P, Dimartino D, Boytard L, Ribeiro-Dos-Santos AM, Vulpescu NA, Westby G, Shen G, Feng X, Hogan MS, Ragonnet-Cronin M, Geidelberg L, Marier C, Meyn P, Zhang Y, Cadley J, Ordoñez R, Luther R, Huang E, Guzman E, Arguelles-Grande C, Argyropoulos KV, Black M, Serrano A, Call ME, Kim MJ, Belovarac B, Gindin T, Lytle A, Pinnell J, Vougiouklakis T, Chen J, Lin LH, Rapkiewicz A, Raabe V, Samanovic MI, Jour G, Osman I, Aguero-Rosenfeld M, Mulligan MJ, Volz EM, Cotzia P, Snuderl M, Heguy A. Sequencing identifies multiple early introductions of SARS-CoV-2 to the New York City region. Genome Res 2020; 30:1781-1788. [PMID: 33093069 PMCID: PMC7706732 DOI: 10.1101/gr.266676.120] [Citation(s) in RCA: 54] [Impact Index Per Article: 13.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2020] [Accepted: 10/20/2020] [Indexed: 11/30/2022]
Abstract
Effective public response to a pandemic relies upon accurate measurement of the extent and dynamics of an outbreak. Viral genome sequencing has emerged as a powerful approach to link seemingly unrelated cases, and large-scale sequencing surveillance can inform on critical epidemiological parameters. Here, we report the analysis of 864 SARS-CoV-2 sequences from cases in the New York City metropolitan area during the COVID-19 outbreak in spring 2020. The majority of cases had no recent travel history or known exposure, and genetically linked cases were spread throughout the region. Comparison to global viral sequences showed that early transmission was most linked to cases from Europe. Our data are consistent with numerous seeds from multiple sources and a prolonged period of unrecognized community spreading. This work highlights the complementary role of genomic surveillance in addition to traditional epidemiological indicators.
Collapse
Affiliation(s)
- Matthew T Maurano
- Institute for Systems Genetics, NYU Grossman School of Medicine, New York, New York 10016, USA.,Department of Pathology, NYU Grossman School of Medicine, New York, New York 10016, USA
| | - Sitharam Ramaswami
- Genome Technology Center, Division of Advanced Research Technologies, Office of Science and Research, NYU Langone Health, New York, New York 10016, USA
| | - Paul Zappile
- Genome Technology Center, Division of Advanced Research Technologies, Office of Science and Research, NYU Langone Health, New York, New York 10016, USA
| | - Dacia Dimartino
- Genome Technology Center, Division of Advanced Research Technologies, Office of Science and Research, NYU Langone Health, New York, New York 10016, USA
| | - Ludovic Boytard
- Center for Biospecimen Research and Development, NYU Langone Health, New York, New York 10016, USA
| | - André M Ribeiro-Dos-Santos
- Institute for Systems Genetics, NYU Grossman School of Medicine, New York, New York 10016, USA.,Department of Pathology, NYU Grossman School of Medicine, New York, New York 10016, USA
| | - Nicholas A Vulpescu
- Institute for Systems Genetics, NYU Grossman School of Medicine, New York, New York 10016, USA.,Department of Pathology, NYU Grossman School of Medicine, New York, New York 10016, USA
| | - Gael Westby
- Genome Technology Center, Division of Advanced Research Technologies, Office of Science and Research, NYU Langone Health, New York, New York 10016, USA
| | - Guomiao Shen
- Department of Pathology, NYU Grossman School of Medicine, New York, New York 10016, USA
| | - Xiaojun Feng
- Department of Pathology, NYU Grossman School of Medicine, New York, New York 10016, USA
| | - Megan S Hogan
- Institute for Systems Genetics, NYU Grossman School of Medicine, New York, New York 10016, USA.,Department of Pathology, NYU Grossman School of Medicine, New York, New York 10016, USA
| | - Manon Ragonnet-Cronin
- MRC Centre for Global Infectious Disease Analysis and Department of Infectious Disease Epidemiology, Imperial College London, London W2 1PG, United Kingdom
| | - Lily Geidelberg
- MRC Centre for Global Infectious Disease Analysis and Department of Infectious Disease Epidemiology, Imperial College London, London W2 1PG, United Kingdom
| | - Christian Marier
- Genome Technology Center, Division of Advanced Research Technologies, Office of Science and Research, NYU Langone Health, New York, New York 10016, USA
| | - Peter Meyn
- Genome Technology Center, Division of Advanced Research Technologies, Office of Science and Research, NYU Langone Health, New York, New York 10016, USA
| | - Yutong Zhang
- Genome Technology Center, Division of Advanced Research Technologies, Office of Science and Research, NYU Langone Health, New York, New York 10016, USA
| | - John Cadley
- Institute for Systems Genetics, NYU Grossman School of Medicine, New York, New York 10016, USA.,Department of Pathology, NYU Grossman School of Medicine, New York, New York 10016, USA
| | - Raquel Ordoñez
- Institute for Systems Genetics, NYU Grossman School of Medicine, New York, New York 10016, USA.,Department of Pathology, NYU Grossman School of Medicine, New York, New York 10016, USA
| | - Raven Luther
- Institute for Systems Genetics, NYU Grossman School of Medicine, New York, New York 10016, USA.,Department of Pathology, NYU Grossman School of Medicine, New York, New York 10016, USA
| | - Emily Huang
- Institute for Systems Genetics, NYU Grossman School of Medicine, New York, New York 10016, USA.,Department of Pathology, NYU Grossman School of Medicine, New York, New York 10016, USA
| | - Emily Guzman
- Genome Technology Center, Division of Advanced Research Technologies, Office of Science and Research, NYU Langone Health, New York, New York 10016, USA
| | | | - Kimon V Argyropoulos
- Department of Pathology, NYU Grossman School of Medicine, New York, New York 10016, USA
| | - Margaret Black
- Department of Pathology, NYU Grossman School of Medicine, New York, New York 10016, USA
| | - Antonio Serrano
- Department of Pathology, NYU Grossman School of Medicine, New York, New York 10016, USA
| | - Melissa E Call
- Department of Dermatology, NYU Grossman School of Medicine, New York, New York 10016, USA
| | - Min Jae Kim
- Department of Dermatology, NYU Grossman School of Medicine, New York, New York 10016, USA
| | - Brendan Belovarac
- Department of Pathology, NYU Grossman School of Medicine, New York, New York 10016, USA
| | - Tatyana Gindin
- Department of Pathology, NYU Grossman School of Medicine, New York, New York 10016, USA
| | - Andrew Lytle
- Department of Pathology, NYU Grossman School of Medicine, New York, New York 10016, USA
| | - Jared Pinnell
- Department of Pathology, NYU Grossman School of Medicine, New York, New York 10016, USA
| | | | - John Chen
- Medical Center IT, NYU Langone Health, New York, New York 10016, USA
| | - Lawrence H Lin
- Department of Pathology, NYU Grossman School of Medicine, New York, New York 10016, USA
| | - Amy Rapkiewicz
- Department of Pathology, NYU Grossman School of Medicine, New York, New York 10016, USA
| | - Vanessa Raabe
- Division of Infectious Diseases and Immunology, Department of Medicine and NYU Langone Vaccine Center, NYU Grossman School of Medicine, New York, New York 10016, USA
| | - Marie I Samanovic
- Division of Infectious Diseases and Immunology, Department of Medicine and NYU Langone Vaccine Center, NYU Grossman School of Medicine, New York, New York 10016, USA
| | - George Jour
- Department of Pathology, NYU Grossman School of Medicine, New York, New York 10016, USA.,Department of Dermatology, NYU Grossman School of Medicine, New York, New York 10016, USA
| | - Iman Osman
- Center for Biospecimen Research and Development, NYU Langone Health, New York, New York 10016, USA.,Department of Dermatology, NYU Grossman School of Medicine, New York, New York 10016, USA
| | | | - Mark J Mulligan
- Division of Infectious Diseases and Immunology, Department of Medicine and NYU Langone Vaccine Center, NYU Grossman School of Medicine, New York, New York 10016, USA
| | - Erik M Volz
- MRC Centre for Global Infectious Disease Analysis and Department of Infectious Disease Epidemiology, Imperial College London, London W2 1PG, United Kingdom
| | - Paolo Cotzia
- Department of Pathology, NYU Grossman School of Medicine, New York, New York 10016, USA.,Center for Biospecimen Research and Development, NYU Langone Health, New York, New York 10016, USA
| | - Matija Snuderl
- Department of Pathology, NYU Grossman School of Medicine, New York, New York 10016, USA
| | - Adriana Heguy
- Department of Pathology, NYU Grossman School of Medicine, New York, New York 10016, USA.,Genome Technology Center, Division of Advanced Research Technologies, Office of Science and Research, NYU Langone Health, New York, New York 10016, USA
| |
Collapse
|
9
|
Shook LL, Shui JE, Boatin AA, Devane S, Croul N, Yonker LM, Matute JD, Lima RS, Schwinn M, Cvrk D, Gardner L, Azevedo R, Stanton S, Bordt EA, Yockey LJ, Fasano A, Li JZ, Yu XG, Kaimal AJ, Lerou PH, Edlow AG. Rapid establishment of a COVID-19 perinatal biorepository: early lessons from the first 100 women enrolled. BMC Med Res Methodol 2020; 20:215. [PMID: 32842979 PMCID: PMC7447612 DOI: 10.1186/s12874-020-01102-y] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2020] [Accepted: 08/13/2020] [Indexed: 12/18/2022] Open
Abstract
BACKGROUND Collection of biospecimens is a critical first step to understanding the impact of COVID-19 on pregnant women and newborns - vulnerable populations that are challenging to enroll and at risk of exclusion from research. We describe the establishment of a COVID-19 perinatal biorepository, the unique challenges imposed by the COVID-19 pandemic, and strategies used to overcome them. METHODS A transdisciplinary approach was developed to maximize the enrollment of pregnant women and their newborns into a COVID-19 prospective cohort and tissue biorepository, established on March 19, 2020 at Massachusetts General Hospital (MGH). The first SARS-CoV-2 positive pregnant woman was enrolled on April 2, and enrollment was expanded to SARS-CoV-2 negative controls on April 20. A unified enrollment strategy with a single consent process for pregnant women and newborns was implemented on May 4. SARS-CoV-2 status was determined by viral detection on RT-PCR of a nasopharyngeal swab. Wide-ranging and pregnancy-specific samples were collected from maternal participants during pregnancy and postpartum. Newborn samples were collected during the initial hospitalization. RESULTS Between April 2 and June 9, 100 women and 78 newborns were enrolled in the MGH COVID-19 biorepository. The rate of dyad enrollment and number of samples collected per woman significantly increased after changes to enrollment strategy (from 5 to over 8 dyads/week, P < 0.0001, and from 7 to 9 samples, P < 0.01). The number of samples collected per woman was higher in SARS-CoV-2 negative than positive women (9 vs 7 samples, P = 0.0007). The highest sample yield was for placenta (96%), umbilical cord blood (93%), urine (99%), and maternal blood (91%). The lowest-yield sample types were maternal stool (30%) and breastmilk (22%). Of the 61 delivered women who also enrolled their newborns, fewer women agreed to neonatal blood compared to cord blood (39 vs 58, P < 0.0001). CONCLUSIONS Establishing a COVID-19 perinatal biorepository required patient advocacy, transdisciplinary collaboration and creative solutions to unique challenges. This biorepository is unique in its comprehensive sample collection and the inclusion of a control population. It serves as an important resource for research into the impact of COVID-19 on pregnant women and newborns and provides lessons for future biorepository efforts.
Collapse
Affiliation(s)
- Lydia L Shook
- Division of Maternal Fetal Medicine, Department of Obstetrics, Gynecology and Reproductive Biology, Massachusetts General Hospital, 55 Fruit Street, Boston, MA, 02114, USA.
| | - Jessica E Shui
- Division of Neonatology and Newborn Medicine, Department of Pediatrics, Massachusetts General Hospital, Boston, MA, USA
| | - Adeline A Boatin
- Department of Obstetrics, Gynecology and Reproductive Biology, Massachusetts General Hospital, Boston, MA, USA
| | - Samantha Devane
- Department of Pediatrics, Massachusetts General Hospital, Boston, MA, USA
| | - Natalie Croul
- Department of Obstetrics, Gynecology and Reproductive Biology, Massachusetts General Hospital, Boston, MA, USA
| | - Lael M Yonker
- Department of Pediatrics, Massachusetts General Hospital, Boston, MA, USA
| | - Juan D Matute
- Division of Neonatology and Newborn Medicine, Department of Pediatrics, Massachusetts General Hospital, Boston, MA, USA
| | - Rosiane S Lima
- Department of Pediatrics, Massachusetts General Hospital, Boston, MA, USA
| | - Muriel Schwinn
- Department of Obstetrics, Gynecology and Reproductive Biology, Massachusetts General Hospital, Boston, MA, USA
| | - Dana Cvrk
- Department of Obstetrics, Gynecology and Reproductive Biology, Massachusetts General Hospital, Boston, MA, USA
| | - Laurel Gardner
- Department of Obstetrics, Gynecology and Reproductive Biology, Massachusetts General Hospital, Boston, MA, USA
| | - Robin Azevedo
- Department of Obstetrics, Gynecology and Reproductive Biology, Massachusetts General Hospital, Boston, MA, USA
| | - Suzanne Stanton
- Department of Obstetrics, Gynecology and Reproductive Biology, Massachusetts General Hospital, Boston, MA, USA
| | - Evan A Bordt
- Department of Pediatrics, Lurie Center for Autism, Massachusetts General Hospital, Boston, MA, USA
| | - Laura J Yockey
- Department of Obstetrics, Gynecology and Reproductive Biology, Massachusetts General Hospital, Boston, MA, USA
- Vincent Center for Reproductive Biology, Massachusetts General Hospital, Boston, MA, USA
| | - Alessio Fasano
- Department of Pediatrics, Massachusetts General Hospital, Boston, MA, USA
| | - Jonathan Z Li
- Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA
| | - Xu G Yu
- Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA
- Ragon Institute of the Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge, MA, USA
| | - Anjali J Kaimal
- Division of Maternal Fetal Medicine, Department of Obstetrics, Gynecology and Reproductive Biology, Massachusetts General Hospital, 55 Fruit Street, Boston, MA, 02114, USA
| | - Paul H Lerou
- Division of Neonatology and Newborn Medicine, Department of Pediatrics, Massachusetts General Hospital, Boston, MA, USA
| | - Andrea G Edlow
- Division of Maternal Fetal Medicine, Department of Obstetrics, Gynecology and Reproductive Biology, Massachusetts General Hospital, 55 Fruit Street, Boston, MA, 02114, USA
- Vincent Center for Reproductive Biology, Massachusetts General Hospital, Boston, MA, USA
| |
Collapse
|
10
|
Maurano MT, Ramaswami S, Zappile P, Dimartino D, Boytard L, Ribeiro-dos-Santos AM, Vulpescu NA, Westby G, Shen G, Feng X, Hogan MS, Ragonnet-Cronin M, Geidelberg L, Marier C, Meyn P, Zhang Y, Cadley J, Ordoñez R, Luther R, Huang E, Guzman E, Arguelles-Grande C, Argyropoulos KV, Black M, Serrano A, Call ME, Kim MJ, Belovarac B, Gindin T, Lytle A, Pinnell J, Vougiouklakis T, Chen J, Lin LH, Rapkiewicz A, Raabe V, Samanovic MI, Jour G, Osman I, Aguero-Rosenfeld M, Mulligan MJ, Volz EM, Cotzia P, Snuderl M, Heguy A. Sequencing identifies multiple early introductions of SARS-CoV-2 to the New York City Region. MEDRXIV : THE PREPRINT SERVER FOR HEALTH SCIENCES 2020:2020.04.15.20064931. [PMID: 32511587 PMCID: PMC7276014 DOI: 10.1101/2020.04.15.20064931] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Effective public response to a pandemic relies upon accurate measurement of the extent and dynamics of an outbreak. Viral genome sequencing has emerged as a powerful approach to link seemingly unrelated cases, and large-scale sequencing surveillance can inform on critical epidemiological parameters. Here, we report the analysis of 864 SARS-CoV-2 sequences from cases in the New York City metropolitan area during the COVID-19 outbreak in Spring 2020. The majority of cases had no recent travel history or known exposure, and genetically linked cases were spread throughout the region. Comparison to global viral sequences showed that early transmission was most linked to cases from Europe. Our data are consistent with numerous seeds from multiple sources and a prolonged period of unrecognized community spreading. This work highlights the complementary role of genomic surveillance in addition to traditional epidemiological indicators.
Collapse
Affiliation(s)
- Matthew T. Maurano
- Institute for Systems Genetics, NYU Grossman School of Medicine, New York, USA
- Department of Pathology, NYU Grossman School of Medicine, New York, USA
| | - Sitharam Ramaswami
- Genome Technology Center, Division of Advanced Research Technologies, Office of Science and Research, NYU Langone Health, New York, USA
| | - Paul Zappile
- Genome Technology Center, Division of Advanced Research Technologies, Office of Science and Research, NYU Langone Health, New York, USA
| | - Dacia Dimartino
- Genome Technology Center, Division of Advanced Research Technologies, Office of Science and Research, NYU Langone Health, New York, USA
| | - Ludovic Boytard
- Center for Biospecimen Research and Development, NYU Langone Health, New York, USA
| | - André M. Ribeiro-dos-Santos
- Institute for Systems Genetics, NYU Grossman School of Medicine, New York, USA
- Department of Pathology, NYU Grossman School of Medicine, New York, USA
| | - Nicholas A. Vulpescu
- Institute for Systems Genetics, NYU Grossman School of Medicine, New York, USA
- Department of Pathology, NYU Grossman School of Medicine, New York, USA
| | - Gael Westby
- Genome Technology Center, Division of Advanced Research Technologies, Office of Science and Research, NYU Langone Health, New York, USA
| | - Guomiao Shen
- Department of Pathology, NYU Grossman School of Medicine, New York, USA
| | - Xiaojun Feng
- Department of Pathology, NYU Grossman School of Medicine, New York, USA
| | - Megan S. Hogan
- Institute for Systems Genetics, NYU Grossman School of Medicine, New York, USA
- Department of Pathology, NYU Grossman School of Medicine, New York, USA
| | - Manon Ragonnet-Cronin
- MRC Centre for Global Infectious Disease Analysis and Department of Infectious Disease Epidemiology, Imperial College London
| | - Lily Geidelberg
- MRC Centre for Global Infectious Disease Analysis and Department of Infectious Disease Epidemiology, Imperial College London
| | - Christian Marier
- Genome Technology Center, Division of Advanced Research Technologies, Office of Science and Research, NYU Langone Health, New York, USA
| | - Peter Meyn
- Genome Technology Center, Division of Advanced Research Technologies, Office of Science and Research, NYU Langone Health, New York, USA
| | - Yutong Zhang
- Genome Technology Center, Division of Advanced Research Technologies, Office of Science and Research, NYU Langone Health, New York, USA
| | - John Cadley
- Institute for Systems Genetics, NYU Grossman School of Medicine, New York, USA
- Department of Pathology, NYU Grossman School of Medicine, New York, USA
| | - Raquel Ordoñez
- Institute for Systems Genetics, NYU Grossman School of Medicine, New York, USA
- Department of Pathology, NYU Grossman School of Medicine, New York, USA
| | - Raven Luther
- Institute for Systems Genetics, NYU Grossman School of Medicine, New York, USA
- Department of Pathology, NYU Grossman School of Medicine, New York, USA
| | - Emily Huang
- Institute for Systems Genetics, NYU Grossman School of Medicine, New York, USA
- Department of Pathology, NYU Grossman School of Medicine, New York, USA
| | - Emily Guzman
- Genome Technology Center, Division of Advanced Research Technologies, Office of Science and Research, NYU Langone Health, New York, USA
| | | | | | - Margaret Black
- Department of Pathology, NYU Grossman School of Medicine, New York, USA
| | - Antonio Serrano
- Department of Pathology, NYU Grossman School of Medicine, New York, USA
| | - Melissa E. Call
- Department of Dermatology, NYU Grossman School of Medicine, New York, USA
| | - Min Jae Kim
- Department of Dermatology, NYU Grossman School of Medicine, New York, USA
| | - Brendan Belovarac
- Department of Pathology, NYU Grossman School of Medicine, New York, USA
| | - Tatyana Gindin
- Department of Pathology, NYU Grossman School of Medicine, New York, USA
| | - Andrew Lytle
- Department of Pathology, NYU Grossman School of Medicine, New York, USA
| | - Jared Pinnell
- Department of Pathology, NYU Grossman School of Medicine, New York, USA
| | | | - John Chen
- Medical Center IT, NYU Langone Health, New York, USA
| | - Lawrence H. Lin
- Department of Pathology, NYU Grossman School of Medicine, New York, USA
| | - Amy Rapkiewicz
- Department of Pathology, NYU Grossman School of Medicine, New York, USA
| | - Vanessa Raabe
- Division of Infectious Diseases and Immunology, Department of Medicine and NYU Langone Vaccine Center, NYU Grossman School of Medicine, New York, USA
| | | | - George Jour
- Department of Pathology, NYU Grossman School of Medicine, New York, USA
- Department of Dermatology, NYU Grossman School of Medicine, New York, USA
| | - Iman Osman
- Center for Biospecimen Research and Development, NYU Langone Health, New York, USA
- Department of Dermatology, NYU Grossman School of Medicine, New York, USA
| | | | - Mark J. Mulligan
- Division of Infectious Diseases and Immunology, Department of Medicine and NYU Langone Vaccine Center, NYU Grossman School of Medicine, New York, USA
| | - Erik M. Volz
- MRC Centre for Global Infectious Disease Analysis and Department of Infectious Disease Epidemiology, Imperial College London
| | - Paolo Cotzia
- Department of Pathology, NYU Grossman School of Medicine, New York, USA
- Center for Biospecimen Research and Development, NYU Langone Health, New York, USA
| | - Matija Snuderl
- Department of Pathology, NYU Grossman School of Medicine, New York, USA
| | - Adriana Heguy
- Department of Pathology, NYU Grossman School of Medicine, New York, USA
- Genome Technology Center, Division of Advanced Research Technologies, Office of Science and Research, NYU Langone Health, New York, USA
| |
Collapse
|
11
|
Argyropoulos KV, Serrano A, Hu J, Black M, Feng X, Shen G, Call M, Kim MJ, Lytle A, Belovarac B, Vougiouklakis T, Lin LH, Moran U, Heguy A, Troxel A, Snuderl M, Osman I, Cotzia P, Jour G. WITHDRAWN: ASSOCIATION OF INITIAL VIRAL LOAD IN SARS-CoV-2 PATIENTS WITH OUTCOME AND SYMPTOMS. THE AMERICAN JOURNAL OF PATHOLOGY 2020:S0002-9440(20)30333-3. [PMID: 32650002 DOI: 10.1016/j.ajpath.2020.06.012] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/19/2020] [Revised: 06/19/2020] [Accepted: 06/23/2020] [Indexed: 12/27/2022]
Abstract
The Publisher regrets that this article is an accidental duplication of an article that has already been published, https://doi.org/10.1016/j.ajpath.2020.07.001. The duplicate article has therefore been withdrawn. The full Elsevier Policy on Article Withdrawal can be found at https://www.elsevier.com/about/our-business/policies/article-withdrawal.
Collapse
Affiliation(s)
| | - Antonio Serrano
- Department of Pathology, NYU Langone Health, New York City, NY
| | - Jiyuan Hu
- Department of Population Health, NYU Grossman School of Medicine, New York City, NY
| | - Margaret Black
- Department of Pathology, NYU Langone Health, New York City, NY
| | - Xiaojun Feng
- Department of Pathology, NYU Langone Health, New York City, NY
| | - Guomiao Shen
- Department of Pathology, NYU Langone Health, New York City, NY
| | - Melissa Call
- Interdisciplinary Melanoma Program, New York University School of Medicine, New York City, NY
| | - Min Jae Kim
- Interdisciplinary Melanoma Program, New York University School of Medicine, New York City, NY
| | - Andrew Lytle
- Department of Pathology, NYU Langone Health, New York City, NY
| | | | | | | | - Una Moran
- Interdisciplinary Melanoma Program, New York University School of Medicine, New York City, NY; Center for Biospecimen Research and Development, NYU Langone Health, New York City, NY
| | - Adriana Heguy
- Department of Pathology, NYU Langone Health, New York City, NY
| | - Andrea Troxel
- Department of Population Health, NYU Grossman School of Medicine, New York City, NY
| | - Matija Snuderl
- Department of Pathology, NYU Langone Health, New York City, NY
| | - Iman Osman
- Interdisciplinary Melanoma Program, New York University School of Medicine, New York City, NY; Center for Biospecimen Research and Development, NYU Langone Health, New York City, NY; Department of Dermatology, NYU Langone Health, New York City, NY
| | - Paolo Cotzia
- Department of Pathology, NYU Langone Health, New York City, NY; Center for Biospecimen Research and Development, NYU Langone Health, New York City, NY
| | - George Jour
- Department of Pathology, NYU Langone Health, New York City, NY; Department of Dermatology, NYU Langone Health, New York City, NY
| |
Collapse
|
12
|
Association of Initial Viral Load in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Patients with Outcome and Symptoms. THE AMERICAN JOURNAL OF PATHOLOGY 2020; 190:1881-1887. [PMID: 32628931 PMCID: PMC7332909 DOI: 10.1016/j.ajpath.2020.07.001] [Citation(s) in RCA: 126] [Impact Index Per Article: 31.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
The dynamics of viral load (VL) of the severe acute respiratory syndrome coronavirus 2 and its association with different clinical parameters remain poorly characterized in the US patient population. Herein, we investigate associations between VL and parameters, such as severity of symptoms, disposition (admission versus direct discharge), length of hospitalization, admission to the intensive care unit, length of oxygen support, and overall survival in 205 patients from a tertiary care center in New York City. VL was determined using quantitative PCR and log10 transformed for normalization. Associations were tested with univariate and multivariate regression models. Diagnostic VL was significantly lower in hospitalized patients than in patients not hospitalized (log10 VL = 3.3 versus 4.0; P = 0.018) after adjusting for age, sex, race, body mass index, and comorbidities. Higher VL was associated with shorter duration of the symptoms in all patients and hospitalized patients only and shorter hospital stay (coefficient = −2.02, −2.61, and −2.18; P < 0.001, P = 0.002, and P = 0.013, respectively). No significant association was noted between VL, admission to intensive care unit, length of oxygen support, and overall survival. Our findings suggest a higher shedding risk in less symptomatic patients, an important consideration for containment strategies. Furthermore, we identify a novel association between VL and history of cancer. Larger studies are warranted to validate our findings.
Collapse
|